Pharmac chief Matthew Brougham explains the reasoning behind the decision to not fund 12 month courses of Herceptin.
He says that if one of his family had breast cancer he would recommend she take the nine week course which is publicly funded and that the jury is still out on the benefits of the year-long course.
The Herald editorial supports the decision and says that even if Pharmac had more money it would probably not spend it on longer courses of Herceptin.
And Kerre Woodham agrees that there is not enough evidence for Phramac to have reversed its decision to fund only nine weeks of the drug.
Update: Macdoctor responds to the Herald.